money.rediff.com
Biocon Biologics Secures US Market Access for Yesintek
Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which product pharmacies and insurers offer or prefer.
Adults with Crohn’s disease or ulcerative colitis who are current or potential ustekinumab candidates, caregivers, clinicians who prescribe biologics, and patient advocates following drug access and cost issues.
What To Know
Biocon Biologics has secured multiple US formulary and market-access agreements for Yesintek (ustekinumab‑kfce), a biosimilar to Stelara (ustekinumab), which the company says is approved for Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
The article lists several major payors and formularies (Express Scripts NPF, Cigna, UnitedHealthcare, CVS Health, Optum Rx, Blue Cross Blue Shield of Michigan, and others) and notes broad coverage start dates for different plan types.
Yesintek is the company’s biosimilar version of ustekinumab and is being added to multiple US formularies, which may increase access and affordability for patients who are eligible for ustekinumab treatment. The report focuses on payer listings and formulary placement rather than clinical data or prescribing guidance.
Coverage details mentioned include commercial, Medicare, and managed Medicaid formulary additions with varying effective dates, and availability in the same presentations as Stelara (several prefilled syringe and vial options). The article quotes the company’s regulatory filing and executive comments about adoption and formulary validation.
This is market-access news: it does not provide new clinical trial results, safety information, or prescribing instructions. Patients should consult their clinicians or insurers about whether Yesintek will be covered for them and about any differences in product naming, substitution policies, or pharmacy processes.
This is a company report about payer formulary placements in the US; it does not present new clinical trial or safety data. Formulary coverage varies by plan and region—patients should check their specific insurer for coverage, prior authorization, or interchangeability policies.
The article cites a regulatory filing and lists payor effective dates but does not change clinical practice on its own.
